Addus HomeCare reported total revenue of $349.4 million for Q2 2025, a 21.8% increase from $286.9 million in Q2 2024.
Adjusted earnings per share increased 10.4% to $1.49 from $1.35 in the prior year quarter.
Adjusted EBITDA rose 24.5% to $43.9 million compared to $35.3 million in Q2 2024, with an adjusted EBITDA margin of 12.6%.
Cash on hand was approximately $91 million at quarter end, with bank debt reduced by $30 million to $173 million, resulting in net leverage under 1x adjusted EBITDA.
Gross margin was stable at 32.6%, with G&A expenses slightly improved to 20% of revenue on an adjusted basis.
Home Health segment revenue declined 6% year-over-year but showed improving profitability due to expense rightsizing.
Hospice segment showed 10% same-store revenue growth and a 7% increase in average daily census.
Personal Care Services segment drove growth with 7.4% organic revenue increase and represented 77% of total revenue.
Adjusted EBITDA grew 5.2% to $114 million, representing 8.1% of net revenue, and adjusted EPS increased 10.8% to $0.41.
Cash flow from operations exceeded $90 million in the quarter, with expectations to generate over $320 million for the full year.
Gross profit was $269 million, up almost 8% versus the prior year, despite gross margin rate pressure from lower-margin limited distribution and rare and orphan therapies.
Option Care Health delivered a strong second quarter with 15% revenue growth year-over-year, driven by mid-teens growth in both acute and chronic therapy portfolios.
The company repurchased $50 million in shares during the quarter, reflecting confidence in the business and its long-term potential.
Dafinchi